Impact of HIPEC (Hyperthermic Intraperitonel Chemotherapy) on Outcome For Gynecologic Cancer Patients in a Community / Teaching Hospital

Document Type

Conference Proceeding

Publication Date

10-2026

Publication Title

International Journal of Gynecological Cancer

Abstract

Introduction: To determine if HIPEC at interval debulking surgery for ovarian cancer affects outcomes. Methods: A chart review identified 63 patients who had HIPEC and 20 patients who did not at the time of interval debulking surgery. Kaplan Meier survival analysis was used to determine significance of progression free survival and overall survival. Student’s t test was used to determine significance of other variables. Results: The cohort had 63 patients who received HIPEC and 20 who did not have HIPEC at the time of interval debulking surgery. Those who received HIPEC were younger on average (p=0.047) compared to controls. HIPEC patients did have a lower mean CA125 at time of surgery (0.0558), but this did not reach significance. The HIPEC patients had a longer time to recurrence (12 months vs 8.71 months, p=0.157), longer progression free survival (22.29 months vs 20.75 months, p=0.1555) and longer overall survival (33.27 months vs 29.95 months, p=0.1533), but none of these outcomes were statistically significant. Conclusion/Implications: Patients receiving HIPEC had increased time to recurrence, progression free survival and overall survival, although this was not statistically significant. Patients selected for HIPEC were significantly younger. They also tended to have a lower mean CA125 at the time of surgery, which implies they had a better response to neoadjuvant chemotherapy. This identifies the question of whether it is HIPEC or if the patient selection for HIPEC that impacts these outcomes. Overall, in our community/teaching hospital, HIPEC increased progression free survival by 2 months and overall survival by 3 months.

Volume

36

Issue

10 Suppl 1

First Page

38

Comments

International Gynecological Cancer Society (IGCS) 2026 Annual Global Meeting, October 1-3, 2026, Montreal, Canada

Last Page

38

DOI

10.1016/j.ijgc.2026.105234

Share

COinS